1. Search Result
Search Result
Isoforms Recommended: TrkA
Results for "

NTRK1

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Inhibitory Antibodies

14

Recombinant Proteins

5

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131003
    Taletrectinib
    2 Publications Verification

    DS-6051b; AB-106; IBI-344

    ROS Kinase Cancer
    Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants [1] .
    Taletrectinib
  • HY-RS09630

    Small Interfering RNA (siRNA) Others

    Ntrk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ntrk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk1 Rat Pre-designed siRNA Set A
    Ntrk1 Rat Pre-designed siRNA Set A
  • HY-RS09629

    Small Interfering RNA (siRNA) Others

    Ntrk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ntrk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ntrk1 Mouse Pre-designed siRNA Set A
    Ntrk1 Mouse Pre-designed siRNA Set A
  • HY-RS09628

    Small Interfering RNA (siRNA) Others

    NTRK1 Human Pre-designed siRNA Set A contains three designed siRNAs for NTRK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NTRK1 Human Pre-designed siRNA Set A
    NTRK1 Human Pre-designed siRNA Set A
  • HY-E70869

    Trk Receptor Neurological Disease
    TRKA (also named NTRK1) is a potential new member of the tyrosine kinase gene family. TRKA is a receptor tyrosine kinase that is phosphorylated in response to NGF. A single transmembrane domain divides TRKA into an extracellular domain, important for NGF binding, and an intracellular tyrosine kinase domain, important for signal transduction. TRKA(NTRK1) Recombinant Human Active Protein Kinase is a recombinant TRKA(NTRK1) protein that can be used to study TRKA(NTRK1)-related functions [1].
    TRKA(NTRK1) Recombinant Human Active Protein Kinase
  • HY-181052

    PROTACs Trk Receptor Cancer
    PROTAC NTRK1 degrader-1 is a wild-type and mutant NTRK1 PROTAC degrader with IC50 values of 4 nM (wild-type), 2 nM (G595R), 5 nM (G667C), and <0.5 nM (F598L). PROTAC NTRK1 degrader-1 catalyzes ubiquitination and subsequent proteasome-mediated degradation of wild-type and mutant (G595R, G667C, F598L) NTRK1. PROTAC NTRK1 degrader-1 can be used for the research of solid tumors [1].
    PROTAC NTRK1 degrader-1
  • HY-131003A

    DS-6051b free base; AB-106 free base; IBI-344 free base

    ROS Kinase Cancer
    Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants [1] .
    Taletrectinib free base
  • HY-185545

    Ligands for Target Protein for PROTAC Trk Receptor Cancer
    NTRK1-ligand-1 (Compound 15) is a NTRK1 ligand. NTRK1-ligand-1 serves as a Ligand for Target Protein for PROTAC, which is applicable to the development and design of PROTAC NTRK1 degraders, such as PROTAC NTRK1 degrader-1 (HY-181052). NTRK1-ligand-1 can be used in the research of solid tumors [1].
    NTRK1-ligand-1
  • HY-156086

    Trk Receptor Cancer
    TRK-IN-24 (compound 10g) is a Trk Receptor inhibitor that inhibits TRKA, TRKC, TRKA G595R, TRKA G667C and TRKA F589L IC50s are 5.21, 4.51, 6.77, 1.42 and 6.13 nM respectively. TRK-IN-24 has antitumor efficacy in BaF3-CD74-NTRK1 G595R and BaF3-CD74-NTRK1 G667C xenograft models. TRK-IN-24 inhibits the proliferation of Ba/F3 cells transfected with single mutants such as SF, GK, and xDFG, with an IC50 of 1.43-47.56 nM [1].
    TRK-IN-24
  • HY-144451

    Trk Receptor Cancer
    TRK-IN-12 (Compound 9e) is a potent inhibitor of TRK (TRK G595R IC50 = 13.1 nM). TRK-IN-12 is a macrocyclic derivative compound. TRK-IN-12 shows significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC50 = 0.080 μM). TRK-IN-12 has shown a better inhibitory effect (IC50 = 0.646 μM) than control agent LOXO-101 in Ba/F3-LMNA-NTRK1-G595R cell line [1].
    TRK-IN-12
  • HY-W1115186

    Ligands for E3 Ligase Others
    CRBN ligand-900 is an E3 ligase ligand that can be used in the recruitment of CRBN protein. CRBN ligand-900 can be connected to the NTRK1 ligand (HY-185545) by a linker to synthesis of PROTAC NTRK1 degrader-1 (HY-181052) [1].
    CRBN ligand-900
  • HY-P990589

    BXL-1H5

    Trk Receptor Inflammation/Immunology
    GBR-900 is a humanized antibody expressed in CHO that targets TrkA/NTRK1. GBR-900 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for GBR-900 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    GBR-900
  • HY-185546

    E3 Ligase Ligand-Linker Conjugates Others
    CRBN ligand-900 Gly is a synthesized E3 ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugate) that incorporates a CRBN ligand and a linker. CRBN ligand-900 Gly can be connected to the target protein ligand to form a PROTAC NTRK1 degrader-1 (HY-181052) [1].
    CRBN ligand-900 Gly
  • HY-101977A

    (R,S)-LOXO-195

    Trk Receptor Cancer
    (R,S)-Selitrectinib (compound 17) is a Trk inhibitor with activity against cancers harboring Trk inhibitor-resistant point mutations in NTRK1, NTRK2, or NTRK3 genes. (R,S)-Selitrectinib can be used for the research of trk inhibitor-resistant cancer [1].
    (R,S)-Selitrectinib
  • HY-180172

    Trk Receptor Apoptosis Cancer
    TRK-IN-33 is a TRK inhibitor. TRK-IN-33 exhibits excellent TRKA G667C degradation (DC50 = 24.69 nM; Dmax > 90%), while sparing the wild-type protein in virto. TRK-IN-33 shows antiproliferative activities against Ba/F3-LMNA-NTRK1 G667C cells with an IC50 value of 2.48 nM. TRK-IN-33 effectively inhibits tumor growth and enhances apoptosis in tumor tissues with no apparent toxicity in vivio. TRK-IN-33 can be used for NTRK fusion−positive cancers research [1].
    TRK-IN-33
  • HY-D3447

    Fluorescent Dye Ferroptosis Others
    LPd peroxida probe-2 (Compound I-1) is a lipid peroxidation fluorescent indicator (Ex = 488 nm, Em = 535 nm). LPd peroxida probe-2 undergoes fluorescence spectral changes in response to lipid hydroperoxides and can be used for Ferroptosis detection and cell imaging.
    LPd peroxida probe-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: